Nektar Therapeutics to Participate in Two Investor Conferences in September

Company Participation in Conferences - Nektar Therapeutics will webcast its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, and the Stifel Virtual Immunology and Inflammation Forum from September 15-16, 2025 [1][4] - Presentations will be accessible via webcast links and on the Investor Events section of the Nektar website, with replays available for 30 days [2] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [3] - The pipeline includes a preclinical bivalent TNFR2 antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified CSF protein NKTR-422 [3] - Nektar is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials aimed at enhancing the immune system's ability to combat cancer [3]